EA200100059A3 - Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции - Google Patents

Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции

Info

Publication number
EA200100059A3
EA200100059A3 EA200100059A EA200100059A EA200100059A3 EA 200100059 A3 EA200100059 A3 EA 200100059A3 EA 200100059 A EA200100059 A EA 200100059A EA 200100059 A EA200100059 A EA 200100059A EA 200100059 A3 EA200100059 A3 EA 200100059A3
Authority
EA
Eurasian Patent Office
Prior art keywords
alkylene
preparation
pharmaceutical compositions
compositions containing
group
Prior art date
Application number
EA200100059A
Other languages
English (en)
Other versions
EA003426B1 (ru
EA200100059A2 (ru
Inventor
Жильбер Лавей
Бернар Симетьер
Тони Вербёрен
Серж Симоне
Жан-Жак Дескомб
Original Assignee
Адир Э Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адир Э Компани filed Critical Адир Э Компани
Publication of EA200100059A2 publication Critical patent/EA200100059A2/ru
Publication of EA200100059A3 publication Critical patent/EA200100059A3/ru
Publication of EA003426B1 publication Critical patent/EA003426B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В заявке описано соединение формулыгде n равно 1-3,m равно 0-6,Rобозначает гидрокси-, алкокси-, арилокси- или арилалкилоксигруппу,Rи Rнезависимо друг от друга обозначают водород, галоген, алкил, алкокси, гидрокси или пергалоалкил,Rобозначает водород или алкил, арилалкил, циклоалкилалкил, арил или циклоалкил,Tобозначает алкилен, O-алкилен, алкилен-O- или С-Салкилен-О-С-Салкилен,G обозначает G- или G-Т-А-группу,где А обозначает арил,Тобозначает связь или алкилен, -O-алкилен, алкилен-O- или С-Салкилен-О-С-Салкилен,Gобозначает -NRR-группу или Gобозначает гетероциклоалкильную группу формулыимеющую от 5 до 7 кольцевых атомов, где Y обозначает атом азота, атом кислорода или СН-группу и R, Rи Rимеют значения, указанные в описании. Также описаны лекарственные средства.
EA200100059A 2000-01-19 2001-01-19 Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции EA003426B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0000623A FR2803848B1 (fr) 2000-01-19 2000-01-19 Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
EA200100059A2 EA200100059A2 (ru) 2001-08-27
EA200100059A3 true EA200100059A3 (ru) 2001-10-22
EA003426B1 EA003426B1 (ru) 2003-04-24

Family

ID=8846042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100059A EA003426B1 (ru) 2000-01-19 2001-01-19 Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции

Country Status (24)

Country Link
US (2) US6469011B2 (ru)
EP (1) EP1118610B1 (ru)
JP (1) JP3462858B2 (ru)
KR (1) KR100517387B1 (ru)
CN (1) CN1166629C (ru)
AR (1) AR027239A1 (ru)
AT (1) ATE222586T1 (ru)
AU (1) AU772978B2 (ru)
BR (1) BR0100107A (ru)
CA (1) CA2332461C (ru)
DE (1) DE60100015T2 (ru)
DK (1) DK1118610T3 (ru)
EA (1) EA003426B1 (ru)
ES (1) ES2180524T3 (ru)
FR (1) FR2803848B1 (ru)
HK (1) HK1038912A1 (ru)
HU (1) HU225747B1 (ru)
MX (1) MXPA01000363A (ru)
NO (1) NO317891B1 (ru)
NZ (1) NZ509455A (ru)
PL (1) PL345236A1 (ru)
PT (1) PT1118610E (ru)
SI (1) SI1118610T1 (ru)
ZA (1) ZA200100565B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006127184A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
TWI474831B (zh) 2012-09-14 2015-03-01 Univ Taipei Medical 免疫調節蛋白於促進傷口癒合或組織損傷治療的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662547B2 (ja) * 1989-01-10 1994-08-17 田辺製薬株式会社 グリシン誘導体
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
JP3284127B2 (ja) * 1990-08-28 2002-05-20 エポック・ファーマシューティカルズ・インコーポレイテッド オリゴヌクレオチドの固相支持体
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
BR9606593A (pt) * 1995-08-21 1997-09-30 Toho Titanium Co Ltd Componente de catalisador sólido e catalisador para a polimerização de olefinas
US6172217B1 (en) * 1996-12-27 2001-01-09 Isis Pharmaceuticals Inc. Method of synthesizing phosphorothioate oligonucleotides
FR2760235B1 (fr) * 1997-02-28 1999-04-09 Adir Nouveaux derives de benzenesulfonylamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP1118610A1 (fr) 2001-07-25
ES2180524T3 (es) 2003-02-16
CN1305989A (zh) 2001-08-01
PL345236A1 (en) 2001-07-30
CA2332461A1 (fr) 2001-07-19
ATE222586T1 (de) 2002-09-15
US20010009915A1 (en) 2001-07-26
HU225747B1 (en) 2007-08-28
EA003426B1 (ru) 2003-04-24
HK1038912A1 (en) 2002-04-04
MXPA01000363A (es) 2002-06-04
HUP0100274A2 (hu) 2002-03-28
AU772978B2 (en) 2004-05-13
US6469011B2 (en) 2002-10-22
PT1118610E (pt) 2002-11-29
JP3462858B2 (ja) 2003-11-05
JP2001226353A (ja) 2001-08-21
HU0100274D0 (en) 2001-03-28
US6545037B2 (en) 2003-04-08
NO317891B1 (no) 2004-12-27
FR2803848B1 (fr) 2002-02-15
EA200100059A2 (ru) 2001-08-27
DE60100015T2 (de) 2003-05-08
EP1118610B1 (fr) 2002-08-21
CA2332461C (fr) 2005-10-25
KR100517387B1 (ko) 2005-09-28
CN1166629C (zh) 2004-09-15
DK1118610T3 (da) 2002-12-16
NZ509455A (en) 2001-06-29
NO20010305D0 (no) 2001-01-18
ZA200100565B (en) 2001-07-30
SI1118610T1 (en) 2002-12-31
KR20010076389A (ko) 2001-08-11
AR027239A1 (es) 2003-03-19
FR2803848A1 (fr) 2001-07-20
US20020137742A1 (en) 2002-09-26
NO20010305L (no) 2001-07-20
BR0100107A (pt) 2001-08-28
DE60100015D1 (de) 2002-09-26
AU1636201A (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
GB8711802D0 (en) Dithioacetal compounds
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
EA200100059A3 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA200500122A1 (ru) Новые соединения, фармацевтические композиции, содержащие их, и способы их использования
EA200000431A3 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
EA200100969A1 (ru) Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
HUP0301553A2 (hu) Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére
ES2019554A6 (es) Procedimiento para preparar n,n -ditrimetoxibenzoilpiperazinas sustituidas en posicion 2"
EA200200665A1 (ru) Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
BG106613A (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
EA200000598A1 (ru) Новые ингибиторы металлопротеазы, способ их получения и содержащие их фармацевтические композиции
EA200400666A3 (ru) Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
DE60119383D1 (de) Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
EA200300029A1 (ru) Новые соединения карбамат и тиокарбамат подофиллотоксина, способ их получения и содержащие их фармацевтические композиции
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции
EA199900460A1 (ru) Производные бензолсульфоамида и лекарственные средства, содержащие упомянутые производные
BG102429A (en) Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means
EA200000527A3 (ru) Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA200100343A3 (ru) Новые гетероциклоалкилбензоциклобутановые и гетероарилбензоциклобутановые производные, способ их получения и содержащие их фармацевтические композиции